[1]陈思言,张伶莉,杨丽华.弥漫性大B 细胞淋巴瘤组织中miR-448 和KDM2B 的水平表达及临床意义[J].现代检验医学杂志,2022,37(04):128-133.[doi:10.3969/j.issn.1671-7414.2022.04.025]
　CHEN Si-yan,ZHANG Ling-li,YANG Li-hua.Expression Levels and Clinical Significance of miR-448 and KDM2B in Diffuse Large B-cell Lymphoma Tissues[J].Journal of Modern Laboratory Medicine,2022,37(04):128-133.[doi:10.3969/j.issn.1671-7414.2022.04.025]
点击复制

弥漫性大B 细胞淋巴瘤组织中miR-448 和KDM2B 的水平表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年04期
页码:
128-133
栏目:
论著
出版日期:
2022-07-15

文章信息/Info

Title:
Expression Levels and Clinical Significance of miR-448 and KDM2B in Diffuse Large B-cell Lymphoma Tissues
文章编号:
1671-7414（2022）04-128-06
作者:
陈思言; 张伶莉; 杨丽华
达州市中心医院血液内科，四川达州 635000
Author(s):
CHEN Si-yan;  ZHANG Ling-li;  YANG Li-hua
Department of Hematology, Dazhou Central Hospital,Sichuan Dazhou 635000, China
关键词:
微小核糖核酸-448; 赖氨酸特异性脱甲基酶2B; 弥漫性大B 细胞淋巴瘤
分类号:
R733；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.04.025
文献标志码:
A
摘要:
目的 探讨微小核糖核酸（micro RNA，miR）-448 和赖氨酸特异性脱甲基酶2B[lysine(K)-specific demethylase2B，KDM2B] 在弥漫性大B 细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）组织中的表达及临床意义。方法 选择2017 年7 月～ 2018 年3 月在达州市中心医院收治的97 例DLBCL 患者作为观察对象，选取同期50 例淋巴结反应性增生 (reactive lymph node hyperplasia，RHL) 组织患者作为对照组，采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR) 法检测DLBCL 组织与RHL 组织中miR-448 和KDM2B mRNA 表达水平，免疫组织化学染色法检测KDM2B蛋白表达水平，分析miR-448 和KDM2B 表达水平与DLBCL 患者临床病理特征的关系，Pearson 分析miR-448 和KDM2B 表达水平的相关性，Kaplan-Meier 生存分析miR-448 和KDM2B 表达与DLBCL 患者生存率的关系以及COX回归模型分析影响DLBCL 患者预后的影响因素。结果 DLBCL 组织中miR-448 表达水平为0.65±0.08，显著低于对照组的1.04±0.19，差异有统计学意义（t=17.473，P ＜ 0.001）；DLBCL 组织中KDM2B mRNA 表达水平为2.89±0.54，显著高于对照组的0.98±0.21，差异有统计学意义（t=24.058，P ＜ 0.001）；免疫组织化学染色结果显示，与对照组比较，DLBCL 组织中KDM2B 蛋白阳性表达率（72.16% vs 22.00%）显著升高，差异有统计学意义（χ2=33.561，P ＜ 0.001）；miR-448 和KDM2B 表达与Ann Arbor 分期、IPI 评分、Hans 分型有关（χ2=4.227 ～ 12.960，均P ＜ 0.05）；与年龄、性别、LDH 水平、ECOG 评分和有无B 症状无关（χ2=0.072 ～ 3.726，均P ＞ 0.05）；相关性分析显示，miR-448 和KDM2B表达水平呈负相关（r=-0.602，P ＜ 0.001）；Kaplan-Meier 生存分析显示，miR-448 高表达组DLBCL 患者三年累积生存率显著高于miR-448 低表达组患者（55.53% vs 31.38%），差异有统计学意义（χ2=7.434，P=0.006）。KDM2B 阳性表达组DLBCL 患者三年累积生存率显著低于阴性表达组患者（31.73% vs 56.67%），差异有统计学意义（χ2=8.877，P=0.006）；COX多因素分析结果显示，Ann Arbor 分期（95%CI=1.567 ～ 4.012，P=0.005），miR-448（95%CI=2.213 ～ 4.478，P=0.001），KDM2B（95%CI=1.506 ～ 4.554，P=0.003）是影响DLBCL 患者不良预后的独立危险因素。结论 在DLBCL 组织中，miR-448 低表达，KDM2B 高表达，且二者表达与DLBCL 病理特征和患者生存有关，可作为DLBCL患者潜在的预后标志物。
Abstract:
Objective To investigate the expression and clinical significance of microRNA (miR)-448 and lysine(K)-specific demethylase 2B（KDM2B） in diffuse large B-cell lymphoma (DLBCL) tissues. Methods A total of 97 DLBCL patients who were admitted to Dazhou Central Hospital from July 2017 to March 2018 were selected as the observation object, and 50 patients with reactive hyperplasia of lymph node (RHL) during the same period were selected as the control group.The expression levels of miR-448 and KDM2B mRNA in DLBCL tissues and RHL were detected by quantitative real-time PCR(qRT-PCR), the expression level of KDM2B protein was detected by immunohistochemical staining method, the relationship between the expression levels of miR-448, KDM2B and clinicopathological characteristics in DLBCL patients was analyzed, the relationship between the expression of miR-448, the correlation between the expression levels of miR-448 and KDM2B was detected by Pearson analysis. KDM2B and the survival rate of DLBCL patients was detected by Kaplan-Meier survival analysis ,and COX regression model was used to analyse the influencing factors of prognosis in patients with DLBCL. Results The expression level of miR-448 in DLBCL tissue was 0.65±0.08, which was significantly lower than 1.04±0.19 in the control group, and the difference was statistically significant (t=17.473, P ＜ 0.001). The expression level of KDM2B mRNA in DLBCL tissue was 2.89±0.54, which was significantly higher than 0.98±0.21 of the control group, the difference was statistically significant (t=24.058, P ＜ 0.001).The results of immunohistochemical staining showed that compared with the control group, the positive expression rate of KDM2B protein in DLBCL（72.16% vs 22.00%）tissue was significantly increased, the difference was statistically significant(χ2=33.561, P ＜ 0.001). The expression of miR-448 and KDM2B was related to Ann Arbor staging,IPI score and Hans classification (χ2=4.227 ～ 12.960, all P ＜ 0.05). But not related to age, gender, LDH level, ECOG score, and the presence or absence of B symptom （χ2=0.072 ～ 3.726，all P ＞ 0.05）. Correlation analysis showed that the expression levels of miR-448 and KDM2B were negatively correlated (r=-0.602, P ＜ 0.001). Kaplan-Meier survival analysis showed that the 3-year cumulative survival rate of DLBCL patients in the miR-448 high expression group was significantly higher than that in the miR-448 low expression group (55.53% vs 31.38%),the difference was statistically significant(χ2=7.434, P=0.006). The 3-year cumulative survival rate of DLBCL patients in the KDM2B positive expression group was significantly lower than that in the negative expression group (31.73% vs 56.67%), the difference was statistically significant(χ2=8.877, P=0.006). COX multivariate analysis showed that Ann Arbor staging(95%CI=1.567 ～ 4.012, P=0.005), miR-448(95%CI=2.213 ～ 4.478, P=0.001) and KDM2B (95%CI=1.506 ～ 4.554, P=0.003) were independent risk factors affecting the poor prognosis of DLBCL patients. Conclusion In DLBCL tissues, miR-448 was lowly expressed and KDM2B was highly expressed, and their expressions were related to the pathological characteristics of DLBCL and patient survival, and may serve as potential prognostic markers for DLBCL patients.

参考文献/References:

[1] WRIGHT G W, HUANG Dawei, PHELAN J D, et al.A probabilistic classification Tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J]. Cancer Cell, 2020, 37(4): 551-568,e14.
[2] 葛晓雯, 姚家美, 朱娜, 等．Calreticulin 在弥漫大B细胞淋巴瘤中的表达及临床意义[J]. 中国癌症防治杂志, 2020, 30(5):347-354. GE Xiaowen, YAO Jiamei, ZHU Na, et al. Expression and clinical implication of calreticulin in diffuse large B-cell lymphoma [J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 30(5):347-354.
[3] 吴荣娟, 邹勇, 马旭东, 等．miR 215,KDM1B 在弥漫性大B 细胞淋巴瘤患者中的表达及临床意义[J].中国实验血液学杂志, 2020, 28(5):1570 -1577. WU Rongjuan, ZOU Yong, MA Xudong, et al.Expression and clinical significance of miR-215 and KDM1B in patients with diffuse large B cell lymphoma[J]. Journal of Experimental Hematology, 2020,28(5):1570 -1577.
[4] FENG Yuhua, ZHONG Meizuo, ZENG Shan, et al.Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance[J]. Epigenomics, 2019, 11(1): 35-51.
[5] 歧红阳, 王云溪, 肖占宇, 等．hsa-miR-448 过表达下调HIF-1α 对结肠癌细胞SW480 作用及机制研究[J]. 中国免疫学杂志, 2019, 35(19):2350-2356. QI Hongyang, WANG Yunxi, XIAO Zhanyu, et al.Effect and mechanism of overexpression of hsamiR-448 by down-regulating HIF-1α on colon cancer cell line SW480 [J]. Chinese Journal of Immunology,2019, 35(19):2350-2356.
[6] ISSHIKI Y, NAKAJIMA-TAKAGI Y, OSHIMA M,et al. KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis[J]. Blood Advances, 2019, 3(17):2537-2549.
[7] 夏苏华, 陈东芹, 覃玲艳, 等．赖氨酸特异性脱甲基酶2B 在胃癌组织表达及临床意义[J]. 中华实验外科杂志, 2018, 35(10):1931-1933. XIA Suhua, CHEN Dongqin, QIN Lingyan, et al.Expression and significance of lysine-specific histone demethylase 2B in gastric cancer [J]. Chinese Journal of Experimental Surgery, 2018, 35(10):1931-1933.
[8] ARBER D, ORAZII A, HASSERJIAN R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20): 2391-2405.
[9] PEI Xinhong, WANG Xinxing, LI Huixiang. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO[J]. International Journal of Biological Macromolecules, 2018, 118(A): 24-30.
[10] 张杰, 韩增胜, 董立新, 等.miR 152 和miR-448 靶向于Rictor 并抑制结直肠癌细胞增殖[J]. 南方医科大学学报, 2019, 39(5):533-539. ZHANG Jie, HAN Zengsheng, DONG Lixin, et al. MicroRNA-152 and microRNA-448 inhibit proliferation of colorectal cancer cells in vitro by targeting Rictor [J]. Journal of Southern Medical University, 2019, 39(5):533-539.
[11] QI Hongfeng, WANG Haifeng, PANG Dabin. MiR-448 promotes progression of non-small-cell lung cancer via targeting SIRT1 [J]. Experimental and Therapeutic Medicine, 2019, 18(3): 1907-1913.
[12] MA Peng, NI Kan, KE Jing, et al. MiR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the e-cadherin repressor ZEB1/2[J]. Experimental Biology and Medicine(Maywood, N.J.), 2018, 243(5): 473-480.
[13] SHAN Changting, FEI Fan, LI Fengzhu, et al. MiR-448 is a novel prognostic factor of lung squamous cell carcinoma and regulates cells growth and metastasis by targeting DCLK1[J]. Biomedicine & Pharmacotherapy,2017, 89(1): 1227-1234.
[14] JIN Jing, WU Yingsheng, ZHOU Dongkai, et al. MiR-448 targets Rab2B and is pivotal in the suppression of pancreatic cancer[J]. Oncology Reports, 2018, 40(3):1379-1389.
[15] ZACHAROPOULOU N, TSAPARA A, KALLERGI G, et al. The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells[J]. Biochimica et Biophysica Acta-Molecular Cell Research, 2018,1865(4): 587-597.
[16] 蒙家华, 况燕, 卢芳芳, 等．KDM2B 过表达慢病毒载体构建及其在人卵巢癌细胞中的表达[J]．山东医药, 2018, 58(5): 5-8. MENG Jiahua, KUANG Yan, LU Fangfang, et al.Construction of lentiviral vector with KDM2B overexpression and its expression in ovarian cancer cells [J].Shandong Medical Journal, 2018, 58(5): 5-8.
[17] QUAN Ming, CHEN Zhiqin, JIAO Feng, et al. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma(PDAC) progression[J]. Journal of Experimental & Clinical Cancer Research, 2020, 39(1): 13.
[18] ZHAO Erhu, TANG Chunling, JIANG Xiaolan, et al. Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells[J]. Cellular Signalling, 2017, 36(1): 222-229.
[19] 易叶叶, 况燕, 蒙家华, 等．赖氨酸特异性脱甲基酶2B 及B 细胞淋巴瘤-2 蛋白、Hrk 蛋白在卵巢癌组织中的表达情况及其临床意义[J]．广西医学, 2019,41(10):1205-1209. YI Yeye, KUANG Yan, MENG Jiahua, et al. Expression and clinical significance of lysine (K)-specific demethylase 2B,B-cell lymphoma-2 protein,and Hrk protein in ovarian cancer tissues [ J]. Guangxi Medical Journal, 2019, 41(10):1205-1209.
[20] HONG Xuehui, XU Yang, QIU Xingfeng, et al.MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B[J]. Oncotarget,2016, 7(16): 22092-22102.
[21] WEI Hui, YU Kang, LIU Yongheng, et al. Tumor expression of miR-448 is a prognostic marker in oral squamous cell carcinoma[J]. BMC Cancer, 2020, 20(1): 756.
[22] WANG Yiwei, ZANG Jin, ZHANG Dongyong, et al.KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth[J]. OncoTargets and Therapy, 2018, 11(1): 201-209.

备注/Memo

备注/Memo:
作者简介：陈思言（1979-)，女，本科，副主任医师，主要从事血液肿瘤方面研究，E-mail： csy110518@163.com。
通讯作者：杨丽华(1963-)，女，本科，主任医师，主要从事血液肿瘤方面研究，E-mail：824826@qq.com。
更新日期/Last Update: 1900-01-01